Genetic Analysis of Pheochromocytomas, Paragangliomas & Associated

Status Recruiting

Clinical Trial Summary

Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.

Clinical Trial Description

Pheochromocytoma and paragangliomas are tumors originated from neuroectoderm cells located in the adrenal or extra-adrenal paraganglia, often leading to increased secretion of hormones known as catecholamines. These tumors represent a potentially curable cause of hypertension and are malignant in about 10-15% of the cases. Approximately 40% of patients with pheochromocytomas and/or paraganglioma have an inherited mutation. In addition, some patients and/or their relatives that are mutation carriers can develop other tumors as part of inherited cancer susceptibility syndromes. Therefore, detection of the susceptibility mutation is important for diagnosis and follow up. However, the susceptibility gene mutation cannot be identified in all cases. Studies that aim to identify novel susceptibility genes for pheochromocytoma are required. The fist aim of this study is to identify novel pheochromocytoma susceptibility genes. Characterization of such gene(s) can improve our understanding of the pathogenesis pheochromocytoma and paraganglioma and have an impact in diagnosis, therapeutic planning and genetic screening of relatives. The second aim of this project is to characterize relationships between mutations and clinical features that can provide insights into clinical surveillance and screening of at-risk individuals. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03160274
Study type	Observational [Patient Registry]
Source	The University of Texas Health Science Center at San Antonio
Contact	Patricia L Dahia, MD,PhD
Phone	2105674866
Email	dahia@uthscsa.edu
Status	Recruiting
Phase
Start date	October 19, 2005
Completion date	December 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06050057` - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Terminated	`NCT05948137` - F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Active, not recruiting	`NCT00436735` - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors	Phase 1
Recruiting	`NCT00669266` - Adrenal Tumors - Pathogenesis and Therapy
Recruiting	`NCT05069220` - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor	Early Phase 1
Recruiting	`NCT06062082` - Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Recruiting	`NCT04573816` - Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Not yet recruiting	`NCT06045260` - "Receptor Radionuclide Therapy With 177Lu-DOTATOC	Phase 2
Completed	`NCT00001147` - Blood Sampling for Neurochemical and Genetic Testing	N/A
Terminated	`NCT00002947` - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer	Phase 1
Completed	`NCT00001229` - Diagnosis and Treatment of Pheochromocytoma	N/A
Completed	`NCT01967576` - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma	Phase 2
Recruiting	`NCT03206060` - Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	Phase 2
Not yet recruiting	`NCT04788927` - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Enrolling by invitation	`NCT03474237` - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms